Tag: Over-the-Counter Drugs and Devices

Displaying 1 - 20 of 77 results.

Pages

The Federal Trade Commission and the U.S. Department of Justice Antitrust Division today issued joint statement detailing an expedited antitrust procedure and providing guidance for collaborations of businesses working to protect the health and safety of Americans during the COVID-19 pandemic.
Nevada-based Health Center, Inc. (HCI) and its owner Peggy Pearce agreed to halt their allegedly deceptive advertising claims about three “cure-all” health and wellness products that targeted older consumers nationwide, pursuant to a settlement with the Federal Trade Commission. The stipulated...
The Federal Trade Commission and U.S. Food and Drug Administration (FDA) have sent warning letters to seven companies allegedly selling unapproved products that may violate federal law by making deceptive or scientifically unsupported claims about their ability to treat coronavirus (COVID-19). The...
Under a settlement with the Federal Trade Commission, the marketers of an electrical nerve stimulation device called Quell have agreed to pay at least $4 million and stop making deceptive claims that the device treats pain throughout the body when placed below the knee and is clinically proven and...
The Federal Trade Commission is mailing 27,174 refund checks totaling over $551,000 to consumers who purchased deceptively marketed “cognitive improvement” supplements.
The Federal Trade Commission sued two companies to stop them from continuing to deceive consumers with false claims that their pills are scientifically proven to alleviate joint pain by growing new bone and cartilage.
In February 2020, the FTC filed a complaint against ZyCal Bioceuticals, a company that marketed a line of joint pain relief products under the brand name Ostinol. The same complaint includes allegations against another company Excellent Marketing Results, Inc. (EMR), which marketed a...
The sellers of a pill called ReJuvenation settled Federal Trade Commission charges that they deceptively claimed that their product is a virtual cure-all for age-related ailments—including cell damage, heart attack damage, brain damage, blindness, and deafness—and even aging itself.The orders...
In January 2020, the sellers of a pill called ReJuvenation settled FTC charges that they deceptively claimed that their product is a virtual cure-all for age-related ailments—including cell damage, heart attack damage, brain damage, blindness, and deafness. The orders settling the FTC...
A Latvian payment processor and its former CEO have agreed to settle the Federal Trade Commission’s complaint against them. The complaint alleges that they engaged in unlawful conduct that enabled a deceptive “free trial” offer scheme by U.S.-based defendants. “Transact Pro helped scammers drain...
The marketers of a dietary supplement called Synovia agreed to settle Federal Trade Commission charges by halting the deceptive tactics they allegedly used to mislead consumers into thinking Synovia could treat arthritis and alleviate joint pain.
The Federal Trade Commission announced a joint warning letter issued with the U.S. Food and Drug Administration (FDA) to Rooted Apothecary, LLC for selling products containing cannabidiol (CBD) online with potentially unsubstantiated claims that the products can treat autism, attention-deficit/...
On October 21, 2019, the FTC announced it had halted the deceptive online marketing tactics of two companies and their principals, the first of which allegedly sold fake indicators of social media influence, and the second of which allegedly used fake product reviews posted by its...
The operators of a deceptive negative option scheme have agreed to a court-ordered preliminary injunction temporarily barring them from a wide range of conduct. The preliminary injunction stops the defendants from misleading consumers about supposedly “free trial” offers, enrolling them in unwanted...
In September 2019, the operators of a deceptive negative option scheme agreed to a court-ordered preliminary injunction temporarily barring them from a wide range of conduct.  The preliminary injunction stops the defendants from misleading consumers about supposedly “free trial”...
The Federal Trade Commission is mailing 2,897 checks totaling more than $113,000 to fully refund consumers who bought FlexiPrin, a deceptively marketed joint pain supplement. The average check amount is $39.18.

Pages